Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Other Accumulated Expenses (2019 - 2025)

aTYR PHARMA (ATYR) has disclosed Other Accumulated Expenses for 6 consecutive years, with $844000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Accumulated Expenses rose 9.75% year-over-year to $844000.0, compared with a TTM value of $844000.0 through Dec 2025, up 9.75%, and an annual FY2025 reading of $844000.0, up 9.75% over the prior year.
  • Other Accumulated Expenses was $844000.0 for Q4 2025 at aTYR PHARMA, up from $769000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $1.1 million in Q4 2023 and bottomed at $672000.0 in Q4 2021.
  • Average Other Accumulated Expenses over 4 years is $846250.0, with a median of $806500.0 recorded in 2024.
  • The sharpest move saw Other Accumulated Expenses plummeted 30.09% in 2024, then increased 9.75% in 2025.
  • Year by year, Other Accumulated Expenses stood at $672000.0 in 2021, then soared by 63.69% to $1.1 million in 2023, then tumbled by 30.09% to $769000.0 in 2024, then grew by 9.75% to $844000.0 in 2025.
  • Business Quant data shows Other Accumulated Expenses for ATYR at $844000.0 in Q4 2025, $769000.0 in Q4 2024, and $1.1 million in Q4 2023.